Table 1.
Randomized controlled trials comparing capecitabine with standard 5-fluorouracil/leucovorin in patients with metastatic colorectal cancer
| Author | Treatment arms | OS (mo) | RR (%) | PFS (mo) | FFS (mo) | Major toxicity |
| Hoff et al[12] | ARM1: LV 20 mg/m2 iv + 5-FU 425 mg/m2/per day iv, days 1-5 every 4 wk | 13.3 | 11.6 | 4.7 | 3.1 | More stomatitis with 5-FU/LV (16% vs 3%) |
| ARM2: Capecitabine 2500 mg/m2 per day, for 14 d every 21 d per os | 12.5 | 25.8 (P = 0.005) | 4.3 | 4.1 | More hand-foot syndrome with capecitabine (18% vs 1%) | |
| Van Cutsem et al[13] | ARM1: LV 20 mg/m2 iv + 5-FU 425 mg/m2 per day iv, days 1-5 every 4 wk | 12.1 | 15 | 4.7 | 4.0 | More stomatitis with 5-FU/LV (13.3% vs 1.3%) |
| ARM2: Capecitabine 2500 mg/m2per day, for 14 d every 21 d per os | 13.2 | 18.9 | 5.2 | 4.2 | More hand-foot syndrome with capecitabine (16.2% vs 0.3%) |
OS: Overall survival; RR: Response rate; PFS: Progression-free survival; FFS: Failure-free survival; LV: Leucovorin; 5-FU: 5-fluorouracil.